TEXAS CANCER GENETICS CONSORTIUM

我们建议德克萨斯州癌症遗传学联合会(TCGC)响应癌症遗传学网络(CGN)RFA CA-97-004。这一TCGC将为中广核带来广泛的专业知识，包括基础和临床癌症遗传学、人类和分子遗传学、机密人类癌症遗传学数据的管理、人类遗传学的社区推广、专业和公众教育，以及关于癌症遗传咨询和检测影响的心理社会研究。癌症控制中心将包括现有的癌症高风险临床人群、德系犹太人人口、乳腺癌、结肠癌、MEN2、NF1和其他遗传易感综合征的登记名单，许多人在数十年的研究中得到跟踪，高癌症风险的患者参与了筛查和早期检测研究或化学预防试验，以及一个大型癌症患者数据库，从中可以确定可能被招募到中广核的高危家庭成员。德克萨斯州的人口在种族构成上是多样化的，TCGC包括在评估西班牙裔和非裔美国人社区在医疗保健方面的需求、向这些社区及其医疗保健提供者提供健康教育以及招募他们参与家族性癌症登记以及临床和研究研究方面具有可靠记录的调查人员。这项申请的资助将为我们的TCGC提供机会，以加强我们在财团内部的互动，为CGN的设计和实施贡献我们的研究经验和专业知识，并利用我们在招募高危患者到CGN方案方面的经验和专业知识。长期目标是帮助确定癌症易感基因、它们的作用机制、频率、外显性和遗传或环境风险修饰物，将这些信息整合到最佳患者管理中，评估需求并提供教育，以解决围绕人类癌症遗传学的伦理和心理社会问题。

We propose a Texas Cancer Genetics Consortium (TCGC) in response to the Cancer Genetics Network (CGN) RFA CA-97-004. This TCGC would bring to the CGN extensive expertise in basic and clinical cancer genetics, human and molecular genetics, management of confidential human cancer genetics data, community outreach in human genetics, professional and public education, and psychosocial studies of the impact of cancer genetic counseling and testing. The TCGC will include existing cancer high risk clinical populations, Ashkenazi Jewish populations, registries of familial breast, colon, MEN2, NF1 and other genetic susceptibility syndromes, many followed in studies for decades, patients at high cancer risk participating in screening and early detection studies or chemoprevention trials, and a large database of cancer patients from which to identify high risk family members for potential recruitment to the CGN. The Texas population is diverse in ethnic makeup, and the TCGC includes investigators with proven track records in assessing needs of the Hispanic and African American communities in health care, in providing health education to those communities and their healthcare providers, and in recruiting their participation in familial cancer registries and clinical and research studies. Funding of this application would provide the opportunity for our TCGC to strengthen our within consortium interactions, to contribute our research experience and expertise to the CGN design and implementation, and to utilize our experience and expertise in recruitment of high risk patients to CGN protocols. The long term goal is to contribute to the identification of cancer susceptibility genes, their mechanisms of action, frequency, penetrance, and genetic or environmental risk modifiers, to integrate this information into optimal patient management, and to assess needs and provide education to address the ethical and psychosocial concerns surrounding human cancer genetics.